Canaccord Genuity Upgrades RTI Biologics (RTIX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts RTIX Hot Sheet
Price: $3.14 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Canaccord Genuity upgraded RTI Biologics (NASDAQ: RTIX) from Hold to Buy with a price target of $5.00.
For an analyst ratings summary and ratings history on RTI Biologics click here. For more ratings news on RTI Biologics click here.
Shares of RTI Biologics closed at $3.93 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Stephens Upgrades MSC Industrial (MSM) to Overweight
- Pirate Gold closes $13.6M brokered private placement
Create E-mail Alert Related Categories
UpgradesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
